Results 31 to 40 of about 6,119 (209)

Potential ‘anti-cancer’ effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells

European Journal of Medical Research, 2023
Background Esketamine, an N-methyl-D-aspartate receptor antagonist, is commonly used for anesthesia and analgesia clinically. It was reported to negatively regulate cell proliferation, metastasis and apoptosis in cancer cells, including lung cancer and ...
Chao Li, Jingpu Shi, Sisi Wei, Huiqun Jia   +3 more
doaj   +1 more source

Efficacy and safety comparison of esketamine-propofol with nalbuphine-propofol for upper gastrointestinal endoscopy in children: a multi-center randomized controlled trial

Frontiers in Pediatrics, 2023
Background and AimsAnesthetics such as propofol, esketamine and nalbuphine are used during the upper gastrointestinal endoscopy to achieve and maintain the desired sedation level.
Xiaosu Zheng, Jinjin Huang, Sisi Wei, Yingying Tao, Yang Shen, Yanting Wang, Pan He, Mazhong Zhang, Ying Sun   +8 more
doaj   +1 more source

The efficacy of nasal administration of esketamine in patients having moderate-to-severe pain after preoperative CT-guided needle localization: a randomized, double-blind, placebo-controlled trial

Frontiers in Medicine
BackgroundWhether nasal administration of esketamine can provide effective analgesia is unclear in patients with acute pain after preoperative CT-guided needle localization.MethodsIn this double-blind, randomized, placebo-controlled trial, patients were ...
Jiangning Xu, Jin Jian, Jin Jian, Yunyun Zhang, Jingxiang Wu, Jingxiang Wu, Yuwei Qiu, Yuwei Qiu   +7 more
doaj   +1 more source

Esketamine vs Control in Bariatric Surgery Patients

, 2023
Methods: We enrolled 68 patients between the ages of 18 and 50 who were planned to have bariatric surgery and had a Body Mass Index of less than 27 kg/m2 and an American Society of Anesthesiologists Physical Status of I to III.
Yang, T (via Mendeley Data)
core   +2 more sources

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park, Yitian Zhou, Volker M. Lauschke   +2 more
wiley   +1 more source

Craving and addictive potential of esketamine as side effects?

, 2022
Introduction: Esketamine was approved for adults with treatment-resistant depression (TRD) in conjunction with an oral antidepressant, and for treating depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Orsolini, Laura, Salvi, Virginio, Volpe, Umberto   +2 more
core   +1 more source

Median effective dose (ED50) of esketamine combined with propofol for children to inhibit response of gastroscope insertion

BMC Anesthesiology, 2023
Background Propofol is the most commonly used drug for procedural sedation during gastroscopy. However, independent use of propofol can lead to increased dosage and additional side effects.
Ming Su, Yichao Zhu, Shupeng Liu, Lijuan Song, Jiangtao Qu, Yong Zhang, Quanyi Zhang   +6 more
doaj   +1 more source

Prophylactic interventions to prevent rebound pain after peripheral nerve block in adults: a systematic review and network meta‐analysis of randomised controlled trials

Anaesthesia, EarlyView.
Summary Introduction Rebound pain after peripheral nerve block is recognised increasingly as a postoperative complication that may diminish the benefits of regional anaesthesia. We undertook a systematic review and network meta‐analysis to evaluate pharmacological strategies for its prevention.
Narinder Pal Singh, Jeetinder Kaur Makkar, Chelsea Zhang, Anuradha Borle, Preet Mohinder Singh   +4 more
wiley   +1 more source

Table_1_Overcoming the myths of esketamine administration: different and not difficult.DOCX

, 2023
Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact
Florian Buchmayer (17436618), Siegfried Kasper (19169)   +1 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source